EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Promising efficacy of teniposide in H3K27M mutant diffuse midline gliomas: a case report

Xiaoman Wang, Tingting Niu, Junxian Xia, Jing Liu, Mengqi Sun

Frontiers in Oncology · 16.04.2026 · 16

DOI: 10.3389/fonc.2026.1784250 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 16.04.2026. Verfasst von Xiaoman Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Second Clinical Medical College of Jinan University, Department of Radiotherapy, Shenzhen People's Hospital, Shenzhen, Guangdong, China. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse midline glioma with H3K27M mutation (H3K27M-mutant DMG) is a rare central nervous system tumor with an extremely poor prognosis. The absence of a standard treatment regimen makes achieving durable survival benefits a major therapeutic challenge. This study reports the case of a 17-year-old male diagnosed with H3K27M-mutant glioma. Following surgical resection and postoperative concurrent chemoradiotherapy, the patient received adjuvant therapy combining teniposide (VM-26) and bevacizumab, which led to significant radiological and symptomatic improvement. By examining the efficacy of this individualized comprehensive strategy—integrating surgery, chemoradiotherapy, and targeted therapy with teniposide—we assess its potential mechanisms and clinical value. This case suggests a potentially effective treatment option for patients with H3K27M-mutant DMG.

Schlagwörter

Stichwörter der Autor:innen

H3K27M mutationchemotherapydiffuse midline gliomatargeted therapyteniposide

Autor:innen und Institutionen

  • The Second Clinical Medical College of Jinan University, Department of Radiotherapy, Shenzhen People's Hospital, Shenzhen, Guangdong, China.
  • The Second Clinical Medical College of Jinan University, Department of Pharmacy, Shenzhen People's Hospital, Shenzhen, Guangdong, China.
  • Departments of Pathology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, Guangdong, China.

Zitieren

APA

Wang, X., Niu, T., Xia, J., Liu, J., & Sun, M. (2026). Promising efficacy of teniposide in H3K27M mutant diffuse midline gliomas: a case report. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1784250

Vancouver

Wang X, Niu T, Xia J, Liu J, Sun M. Promising efficacy of teniposide in H3K27M mutant diffuse midline gliomas: a case report. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1784250

BibTeX
@article{Wang2026,
  author = {Wang, Xiaoman and Niu, Tingting and Xia, Junxian and Liu, Jing and Sun, Mengqi},
  title = {Promising efficacy of teniposide in H3K27M mutant diffuse midline gliomas: a case report},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1784250}
}
Kostenlos starten →